<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020821</url>
  </required_header>
  <id_info>
    <org_study_id>4-2021-0853</org_study_id>
    <nct_id>NCT05020821</nct_id>
  </id_info>
  <brief_title>Interscalene Brachial Plexus Catheter Versus Single-shot Interscalene Block With Intravenous Dexmedetomidine for Shoulder Arthroplasty</brief_title>
  <official_title>Interscalene Brachial Plexus Catheter Versus Single-shot Interscalene Block With Intravenous Dexmedetomidine for Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shoulder arthroplasty is associated with significant postoperative pain. Appropriate pain&#xD;
      control after shoulder arthroplasty is crucial for postoperative rehabilitation and patient&#xD;
      satisfaction. Interscalene brachial plexus block (IBPB) is a commonly employed regional&#xD;
      anesthetic technique for shoulder arthroplasty, and a continuous catheter is often placed to&#xD;
      extend the analgesic benefit of the block. However, continuous IBPB is more costly and&#xD;
      time-consuming than single-shot IBPB. Recent evidence suggests that intravenous (IV)&#xD;
      dexmedetomidine (DEX) prolong the analgesic duration after single-shot IBPB. The&#xD;
      investigators will compare continuous IBPB with single-shot IBPB with IV DEX in patients&#xD;
      undergoing shoulder arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale pain score</measure>
    <time_frame>24 hours afer the end of surgery</time_frame>
    <description>Pain intensity at rest will be evaluated by an 11-point numeric rating scale (NRS: 0 = no pain, 10 = worst imaginable pain) 24 hours after the surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Shoulder Arthroplasty</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Single-shot interscalene block with intravenous dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants receiving single-shot interscalene block with intravenous dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous interscalene brachial plexus block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants receiving continuous interscalene brachial plexus block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single-shot interscalene block with intravenous dexmedetomidine</intervention_name>
    <description>During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot interscalene brachial plexus block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.</description>
    <arm_group_label>Single-shot interscalene block with intravenous dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous interscalene brachial plexus block</intervention_name>
    <description>Continuous interscalene block will be performed under ultrasound guidance and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 6 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.</description>
    <arm_group_label>Continuous interscalene brachial plexus block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 Patients aged 19 years old or older, with American Society of Anesthesiologists Physical&#xD;
        Status 1-3, and scheduled for elective shoulder arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or intolerance to any of the drugs used in the study&#xD;
&#xD;
          2. Heart failure&#xD;
&#xD;
          3. Hepatic or renal insufficiency&#xD;
&#xD;
          4. Opioid dependency&#xD;
&#xD;
          5. Coagulopathy&#xD;
&#xD;
          6. Pre-existing neurologic or anatomic deficits in the upper extremities&#xD;
&#xD;
          7. Severe psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaewon Jang</last_name>
    <phone>82-2-2224-1637</phone>
    <email>jaewonjang2020@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaewon Jang</last_name>
      <phone>82-2-2224-1637</phone>
      <email>jaewonjang2020@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

